Diabetes News

ORLANDO — Isuzinaxib, a pan-NOX inhibitor modulating oxidative stress by Aptabio significantly reduced urine albumin-to-creatinine ratio in patients with type 2 diabetes and chronic kidney disease, according to data at ASN Kidney Week.

CHICAGO — A meta-analysis of 13 large SGLT2 inhibitor trials, including the recently published EMPA-KIDNEY trial, indicates that the drug class reduces CV and renal outcomes across all high-risk groups, with and without type 2 diabetes.

ORLANDO —Empagliflozin reduced kidney disease progression and cardiovascular death in patients with chronic kidney disease, according to data presented at ASN Kidney Week.

ORLANDO — SGLT2 inhibitors reduce the risk and progression of chronic kidney disease and AKI regardless of diabetes status, according to data presented at ASN Kidney Week.

A group of representatives from national and international endocrine, nephrology and pediatric societies has proposed changing the name of diabetes insipidus to arginine vasopressin deficiency and arginine vasopressin resistance.

The American Association of Clinical Endocrinology has issued a grade-A recommendation to use Kerendia for certain patients with chronic kidney disease associated with type 2 diabetes.

Healio is continuing its partnership with the Cardiometabolic Health Congress in support of the 17th Annual Cardiometabolic Health Congress: The Present and Future of Cardiometabolic Health in Boston.

Healio and the Cardiometabolic Health Congress are proud to partner for the 17th Annual Cardiometabolic Health Congress: The Present and Future of Cardiometabolic Health in Boston this fall.

As a valued ally in delivering the latest news, resources and education to busy medical providers, Healio has committed its support to the 17th Annual Cardiometabolic Health Congress: The Present and Future of Cardiometabolic Health.

Researchers identified the distance between a household and a supermarket as a risk factor for chronic kidney disease, hypertension and diabetes development.